Arcutis Partners with Sato for Topical Roflumilast

Arcutis and Sato Enter Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan

Overview

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) and Sato Pharmaceutical Co., Ltd. have announced a strategic collaboration and licensing agreement for the development, production, and commercialization of topical roflumilast in Japan. Roflumilast, a next-generation phosphodiesterase type 4 (PDE4) inhibitor, will be made available in cream and foam formulations to address various dermatological conditions such as plaque psoriasis, seborrheic dermatitis, and atopic dermatitis, with potential expansion to other conditions in the future.

Words from Arcutis

Arcutis, expressed enthusiasm about the partnership with Sato, emphasizing their shared commitment to innovating treatments for immune-mediated skin diseases. He highlighted the significant market potential for topical roflumilast in Japan and the financial benefits for Arcutis.

Words from Sato 

Sato Pharmaceutical, echoed this sentiment, citing Arcutis' expertise and success in the dermatology field. He emphasized the potential impact of roflumilast in addressing the needs of patients with various inflammatory skin conditions in Japan.

Responsibilities of Arcutis

As part of the agreement, Arcutis will receive an upfront payment of $25 million, with the possibility of an additional $40 million contingent on meeting certain regulatory and sales milestones. Arcutis will also be entitled to tiered, low double-digit percentage royalties.

Responsibilities of Sato

Sato will take charge of the development, manufacturing, and commercialization of roflumilast cream and foam in Japan, while Arcutis will retain responsibility for these products in the United States and other regions, excluding Greater China and Southeast Asia.

About Roflumilast

Roflumilast, a potent PDE4 inhibitor, is being developed by Arcutis as a once-daily, nonsteroidal topical treatment for various dermatological conditions. The drug targets PDE4, an enzyme implicated in inflammation, offering a safe and effective alternative for patients.

ZORYVE Indications

ZORYVE cream and foam formulations have been indicated for the topical treatment of plaque psoriasis and seborrheic dermatitis, respectively, with specific safety information provided, including contraindications and common adverse reactions.

Partnership for Future 

The collaboration between Arcutis and Sato represents a significant step forward in addressing the unmet needs of individuals suffering from immune-mediated skin diseases in Japan, leveraging the strengths and expertise of both companies to bring innovative treatments to patients.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!